Tag: Blood Cancers

Search News
Categories
Archives
CRUK Barts Centre welcomes two new Group Leaders

8th November 2018

We are pleased to welcome two new members of academic staff to the CRUK Barts Centre- Professor Victoria Sanz-Moreno and Professor Kamil R Kranc.

Read more

Accelerator Award to improve early detection and intervention of blood cancers

9th October 2018

BCI researchers are lead members of an international team to be funded by an Accelerator Award, which will bring together scientists from the UK, Spain and Italy in a bid to improve early detection and intervention of blood cancers.

Read more

Blood Cancer Awareness Month 2018

28th September 2018

Blood Cancer Awareness Month takes place every September to raise awareness of the challenges faced by those living with blood cancer. In the UK, blood cancer is the fifth most common cancer, with 240,000 people living with the disease and 38,000 people being diagnosed with a type of blood cancer each year.

Read more

CRUK Gibraltar Committee visit the BCI

18th July 2018

We were recently visited by two members of the CRUK Gibraltar Committee, Giovi and Deborah, who came to the BCI for a laboratory tour with Dr Ana Rio-Machin, a postdoctoral researcher in the Centre for Haemato-Oncology. Ana’s research focuses on leukaemia, a type of blood cancer in which patients present an abnormal growth of white blood cells.

Read more

Follicular lymphoma marked by spatial tumour heterogeneity

23rd March 2018

A research team at the BCI, Queen Mary University of London, led by Dr Jessica Okosun, Centre for Haemato-Oncology, has found that tumours at different sites within the same patient with follicular lymphoma can be genetically diverse. This suggests that a sole biopsy is incapable of capturing all the genetic events in any given individual and presents a significant challenge when providing targeted therapies to treat this disease.

Read more

Some leukaemia patients may be missing out on new treatments

11th January 2018

Patients with an aggressive form of leukaemia, currently ineligible for any type of targeted therapy, may in fact benefit from new drugs, according to new research by Barts Cancer Institute at Queen Mary University of London.

Read more

Search News
Categories
Archives